Drug Profile
Ramipril/piretanide
Alternative Names: Arelix; Prilace; TrilaxLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antihypertensives; Heterocyclic bicyclo compounds; Sulfonamides
- Mechanism of Action ACE inhibitors; Diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Essential hypertension
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 21 Jan 2000 Launched for Essential hypertension in Belgium (PO)
- 21 Jan 2000 Launched for Essential hypertension in Germany (PO)